



In The Name Of God

# **Polymeric Engineering of Nanoparticles for Highly Efficient Multifunctional Drug Delivery Systems**

**PRESENT BY:**

**MAEDE KHAZAEI**

**ADVISER :**

**DR. AHMADPOUR YAZDI**

# List of contents

➤ Article Information .....	3
➤ Journal Information .....	4
➤ Abstract.....	5
➤ Introduction.....	6
➤ Assume .....	14
➤ Materials .....	15
➤ Methods.....	16
➤ Results and Discussion.....	27
➤ Future Perspective .....	44

# Article Information

Author:

Beatrice Fortuni et al

University : Belgium

- ❖ Received: 16 July 2018
- ❖ Accepted: 16 January 2019
- ❖ Published: 25 Feb. 2019

# Journal Information

## “Scientific Reports”

- 2-year impact factor: 4.122
- 5-year impact factor: 4.609
- Immediacy index: 0.576
- Eigenfactor ® score: 0.71896
- Article influence score: 1.356

# Abstract

- ▶ Developed a multifunctionalized DDS that combines **high specificity** towards cancer cells with endosomal escape capabilities
- ▶ The polymeric engineering here developed enhances the performance of DDS at **low drug dose**, holding great potential for anticancer therapeutic applications.

# Introduction

## **Why Mesoporous Silica Nanoparticles?!! (MSNP)**

- ❖ Biocompatibility
- ❖ High loading capacity
- ❖ Chemical stability
- ❖ Straightforward synthesis/surface functionalization

Have not been translocated into the clinical stage yet!!

To promote the specific internalization of nanoparticles to certain cancer cells;

Employment of specific ligands, which can bind to receptors overexpressed in tumor cells and trigger particle internalization via endocytosis

Hyaluronic acid & Glycoprotein receptor overexpressed in many solid tumor cells

(HA) ↔ (CD44)



- ▶ External materials taken up via endocytosis
- ▶ Normally sorted out in **Endocytic** vesicles (endosomes & lysosomes)
- ▶ Ejected to the extracellular matrix via **Exocytosis**

**What is the problem ????**



**Non-Coated MSNPs** co-localize with the endo-  
lysosomes in the early stage of incubation, & are  
quickly **exocytosed**

**HA-coated MSNPs** are internalized via **CD44-mediated Endocytosis** & are subjected to same endocytic system, ending up in the acidic **cellular compartments** within few hours of incubation, & being ejected via exocytosis within **48 h**

# Problems in DDS

11


- The **Endo-/Exocytosis** process
- The **Low lysosomal pH** (4.5–5.5 for normal cells and 3.5–5 for cancer cells)
- The strong **Enzymatic activity**
- The **Fast exocytosis** of the **Nanocarriers**
- The **DDS** can be **exocytosed** to the extracellular matrix before releasing all its cargo

So:

The employment of **Cationic Polymers**, in particular **Polyethylenimine** (PEI), is a promising strategy, as it is non-immunogenic and easier to scale up, compared to other agents, such as synthetic fusogenic peptides.

&

**“Proton Sponge Effect”** of PEI





# Assume

- ▶ the **Endosomolytic activity** of the **PEI** layer
- ▶ the addition of a PEI layer can **slow down** the **Exocytosis** rate of **MSNPs**
- ✓ A facile method to functionalize MSNPs with a polymeric bilayer, which simultaneously combines the active targeting action of **HA** & **PEI-mediated** endosomal escape

# Material

15

**Materials.** Tetraethyl orthosilicate (TEOS, 98%), cetyltrimethylammonium chloride solution (CTAC, 25% in H<sub>2</sub>O), triethanolamine (TEA, 99%), hydrochloric acid (HCl, 1 N), rhodamine B basic violet 10 [RhodB, 93%], fluorescein 5(6)-isothiocyanate (FITC, ≥90% HPLC), polyethyleneimine solution (PEI, 50% w/v in H<sub>2</sub>O), N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide (EDC, 97%), N-hydroxysulfosuccinimide sodium salt (sulfo-NHS, ≥98% HPLC), doxorubicin hydrochloride (Dox, suitable for fluorescence, 98–102%, HPLC), sodium acetate buffer solution, MES hydrate (titration, ≥99.5%), hyaluronidase type I-S (Hyal-1, from bovine testes), hyaluronidase Type II (Hyal-2, from sheep testes) were purchased from Sigma Aldrich. Sodium hyaluronate (HA, research grade, 289 kDa) was obtained from LifeCore BioMedical. Dulbecco's modified eagle medium (DMEM), and LysoTracker RED DND-99 were purchased from Molecular Probes. Gentamicin, Dulbecco's phosphate buffered saline (PBS, no calcium, no magnesium), Hank's balanced salt solution (HBSS, no phenol red), GlutaMaxi supplement, fetal bovine serum (FBS, South America origin), Ethanol (absolute, 99.9%), Vybrant DiO cell-labeling solution were purchased from ThermoFisher Scientific. Trypan blue solution (0.4%, TC grade) was purchased from Life Science. All the chemicals were used without further purifications.



# Methods:

16

## 1- HAPEI-MSNps Preparation:

synthesis of **MSNPs** → The loading of **RhodB** and **FITC** →  
MSNPs dispersed in phosphate buffer (pH 9) to **increase the loading efficiency**

↓  
the **Dox** soaking → mixtures under magnetic stirring (500 rpm) overnight

== **MSNPs RhodB/FITC/Dox**

**PEI** in H<sub>2</sub>O at pH 7 and added to loaded-MSNPs in milli-Q water → about 3 h under magnetic stirring → **HA** were dissolved in 10 mL of MES buffer → stirring for 30 minutes for the activation of the **carboxylic groups** → **carboxyl-activated HA** added to 3 mL of **PEI-MSNPs\_X**

== **HAPEI-MSNPs\_X**

- Analyzed with UV-VIS spectrometer in order to estimate the soaked cargo concentrations via absorbance

# Methods

## HAPEI-MSNps - X characterization:

- ❖ transmission electron microscopy (**TEM**): for **size, shape & porosity**
- ❖ collecting **wide-field images** and the **relative emission spectrum** of MSNPs\_Dox/RhodB/ FITC: The **loading**
- ❖ **inverted optical microscope** (TiU, Nikon): **measurements**
- ❖ **Nd:YAG laser** : applied on RhodB samples

# Methods

19

## Cellular uptake: **NIH3T3** and **A549** cell lines

All cells  $\xrightarrow[\text{in 25 cm}^2 \text{ cell culture flasks}]{\text{at 37 } ^\circ\text{C, 5\% CO}_2,}$   $\xrightarrow{\text{the confluency reached 80\%}}$  in DMEM medium

containing 10% FBS, 1% L-glutamax and 0.1% gentamicin

Then

cultured in 35-mm **glass bottom dishes** for **confocal imaging**

- (NIH3T3 cell lines: Embryonic fibroblast cells)
- (A549 cell lines: Adenocarcinomic human alveolar basal epithelial cells)



# Methods

20

## Cellular uptake:

For verifying the effect of different functionalization on the uptake;

RhodB-loaded particles (MSNPs\_RhodB, PEI-MSNPs\_RhodB & HAPEI-MSNPs\_RhodB)



- I. incubated with NIH3T3 and A549 cells
- II. plasma membrane was stained with DiO
- III. visualized under a Confocal Fluorescence Microscope
- IV. Fluorescence intensity analysis was performed by MATLAB software

## Intracellular trafficking: fluorescence microscopy



- ✓ FITC : In order to **track** the **intracellular** fate of the **particles** (MSNPs\_FITC, PEI-MSNPs\_FITC, HAPEI-MSNPs\_FITC) with **A549** cells for 3 h.
- ✓ **Washed** with **PBS** three times : **remove** the **residual** extracellular **particles**
- ✓ **Confocal fluorescence** measurements after the washing (data of 3 h of incubation)  
(**other copies** of the same samples in **fresh medium** and placed back in the **incubator** for measurements after **24** and **48** h)
- ✓ **stained** with **Lysotracker Red**: For the **acidic compartment imaging**, endo/ lysosomes
- ✓ **Images** were processed using **FV10-ASW Viewer Software**





- Pearson correlation coefficient (**PCC**) analysis by using **MATLAB** software

PCC values	indicate that:
Near 0	the fluorescence intensities of the two channels are <b>uncorrelated</b>
Close to 1	the two fluorescence intensities are perfectly linearly <b>related</b>

$$PCC = \frac{\sum_i (R_i - \bar{R}) \cdot (G_i - \bar{G})}{\sqrt{\sum_i (R_i - \bar{R})^2 \cdot \sum_i (G_i - \bar{G})^2}},$$







# Methods

24

## Drug release in vitro:

- 1) 3 different pH **buffers**: Acetate buffer (pH 4.5), MES buffer (pH 6) and PBS (pH 7.4)
- 2) Add **Dox-incorporated** particles
- 3) **Hyal-1** and **Hyal-2** add to HAPEI-MSNPs\_Dox in acetate and MES buffer for...
- 4) at different incubation time (**0–72 h**),
- 5) Estimate the **concentration** of the **Dox released** by collecting the absorbance at **490 nm**.

# Methods

25

## Drug release in Cellulo.:

10  $\mu$ L of HAPEI-MSNPs\_Dox + 1 mL of medium containing A549 cells



✓ in the incubator for 3 h

taining A549 cells on a glass-bottom dish. The dish was then placed in the incubator for 3 h. Subsequently, the un-internalized particles were washed away with PBS washing (x3) and the cells were measured by using a confocal microscope (FV 1000 Olympus microscope) without any staining, obtaining data of 3 h of incubation. On the other hand, after the PBS washing, other copies of the same samples were suspended in fresh medium and placed back in the incubator for measurements after 24 and 48 h. Differential interference contrast (DIC) images were collected to visualize the cells and Dox emission was detected by using a 488 nm laser (5  $\mu$ W, power density  $\sim 5.3$  kW/cm<sup>2</sup>), a 100x oil objective (N.A. 1.4) and a bandpass filter 600–670 nm.

# Methods

26

## Anticancer efficiency:

Carry out viability tests;

- I. **Seed** the cells with 1 mL of **medium**
- II. **aliquots** of 2, 4, 6, 8 and 10  $\mu\text{L}$  solutions **containing** HAPEI-MSNPs\_Dox, free Dox & empty HAPEI-MSNPs (Dox= 80, 160, 240, 320 and 400 nM & particles= 20, 40, 60, 80, 100  $\mu\text{g/mL}$ )
- III. Incubated overnight, wash & ...
- IV. The **viability** was estimated: after the **treatment** (HAPEI-MSNPs\_Dox, free Dox and empty particles) with a **control** dish
- V. **KOVA** system protocol





# Results & Discussion

27


## Preparation and characterization of multifunctional MSNPs.:

- ✓ **Synthesize** MSNPs using the biphase stratification method that particles with a **pore size of ~2.8 nm**
- ✓ Properties: **size (120nm)** & **shape homogeneity**,  
**No aggregates** & **uniform mesoporous frame**



TEM images of uncoated MSNPs







**Cargo loading into MSNPs:** wide-field **fluorescence** images (a-c) and relative emission spectra (insets) of MSNPs loaded with RhodB (a), FITC (b) and Dox (c). Emission spectra were collected by focusing the laser on one bright spot.

# Results & Discussion


- ❖ MSNPs were coated with PEI for providing the DDS with endosomal escape capability
- ❖ ionization percentage enables the formation of a PEI shell on the MSNP surface via electrostatic interaction. The presence of the PEI layer on MSNPs was demonstrated by the drastic change in the zeta potential of the particles after the coating







after conjugation with HA, the edge contrast increases, The halo displayed in Fig. e,f was never observed for bare MSNPs (FE-SEM images)





# Results & Discussion

31



## Cellular uptake: HA-mediated active targeting;

- ▶ Different particles into two mammalian cell lines for **targeting efficiency** & the cell **specificity** of the external functionalization with **HA**
- ▶ RhodB-loaded MSNPs with different coatings + A549 cells (CD44-overexpressing cells) & NIH3T3 (CD44-inactive cells)



**Influence of surface modification on the cellular uptake of MSNPs.**  
(Fluorescence images )





**Intracellular trafficking: PEI-induced endosomal rupture**

# Results & Discussion



34

- ❖ coating of nanoparticles with specific polymers ↑ the rupture of the endo-/lysosomes and further escape to the cytosol
- ❖ Both fluorescence and electron microscopy images demonstrate an ↑ of the endosomal escape efficiency with HA-PEI coating compared to using PEI alone
- ❖ At low pH, the inclusion of an extra polymeric layer can, ↑ both the buffering capacity and the polymeric swelling, contributing to the destabilization of the endo-/lysosomal membrane.


Low magnification

High magnification



Au@MSNPs



PEI-Au@MSNPs



HAPEI-Au@MSNPs





# Results & Discussion

36




## Drug release in vitro:


- Doxorubicin for therapeutic effectiveness & fluorescent properties
- DDSs should be combined with a controlled release at the specific target.
- bare MSNPs, the environmental pH plays a crucial role on the drug release kinetics. the release rate of Dox in vitro is + at acidic pH, although a relatively smaller amount can be released at neutral pH as well.




# Results & Discussion

37

- the HA-PEI polymeric bilayer will function as a capping agent, preventing the leakage of the drug before reaching the intracellular environment
- At neutral pH, according to the pKa values of PEI and silica hydroxyl groups, the electrostatic interactions guarantee a stable attachment of the PEI shell to the particles,  the discharge of Dox in blood circulation
- At acidic pH, as the majority of the hydroxyl groups of the silica particles are protonated, the electrostatic interactions are minimized,  the capping effect of the polymeric coating and  the drug release in the cellular acidic compartments



➡ only **enzyme-mediated degradation** of the **polymeric coating**, which occurs exclusively in the cellular environment, **triggers drug release** from the particles



### Drug release in Cellulo.:

Fluorescence images of **Dox released** from HAPEI-MSNPs\_Dox inside **A549 cells** after 3, 24 and 48 h


# Results & Discussion

40

## Anticancer Efficiency: cell viability tests:

In order to evaluate the efficiency of polymer-coated particles as anticancer DDSs, cell viability 72 h after treatment with free Dox, Dox-loaded HAPEI-MSNPs & empty HAPEI-MSNPs, at different concentration of drug/particles

- (high uptake, endosomal escape & controlled drug released)





# Results & Discussion

41

- our **DDS** has great therapeutic potential, specifically towards **CD44-overexpressing** cancer cells
- The **high therapy efficiency** achieved at **low drug concentrations** is strictly related to:
  - the **fast internalization** rate (HA coating targeting effect)
  - to the improved **endosomal release** (with consequent **retention** of the **particles** in the **cytoplasm**, HA-PEI shell inducing endosomal rupture),
  - **control drug release** overtime (enzymatic polymeric digestion)

# Results & Discussion

42

- 1) HA & PEI layers provide the DDs with active targeting & endosomal escape capability, enhancing the therapeutic efficiency
- 2) Dox-loaded HAPEI-MSNPs exhibit great killing efficiency at low drug concentrations, which was comparable with that of pure Dox, but with specificity towards CD44-overexpressing cancer cells






Great potential DDs for tumor therapy applications ;

- ✓ endosomal escape capacity
- ✓ controlled drug release
- ✓ Consequently
- ✓ high therapeutic effect
- ✓ targeting capability towards cancer cells

# Future Perspective

- ▶ The **polymeric functionalization** proposed can be applied to a wide range of **nanocarriers** towards the **increase of the therapeutic power** at low drug dose and the decrease of exocytosis rate, drastically reducing the side effects of anti-cancer drugs.



Change your thoughts & you  
change your world.

thanks